{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:47:58Z","timestamp":1786718878659,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/jcrt.jcrt_47_18","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T06:02:55Z","timestamp":1549346575000},"page":"1131","source":"Crossref","is-referenced-by-count":12,"title":["Ligand- and structure-based pharmacophore modeling, docking study reveals 2-[[4-[6-(isopropylamino) pyrimidin-4-yl]-1H-pyrrolo[2,3-b] pyridin-6-yl] amino] ethanol as a potential anticancer agent of CDK9\/cyclin T1 kinase"],"prefix":"10.4103","volume":"15","author":[{"given":"Afzal","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChandanKumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.251622-1","first-page":"261","volume-title":"Cyclin-dependent kinases: Engines, clocks, and microprocessors","author":"Morgan","year":"1997","journal-title":"Annu Rev Cell Dev Biol"},{"key":"key-10.4103\/0973-1482.251622-2","first-page":"471","volume-title":"Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle","author":"Nigg","year":"1995","journal-title":"Bioessays"},{"key":"key-10.4103\/0973-1482.251622-3","first-page":"131","volume-title":"The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif"},{"key":"key-10.4103\/0973-1482.251622-4","first-page":"28345","volume-title":"Flavopiridol inhibits P-TEFb and blocks HIV-1 replication","author":"Chao","year":"2000","journal-title":"J Biol Chem"},{"key":"key-10.4103\/0973-1482.251622-5","first-page":"859","volume-title":"ATP-site directed inhibitors of cyclin-dependent kinases","author":"Gray","year":"1999","journal-title":"Curr Med Chem"},{"key":"key-10.4103\/0973-1482.251622-6","first-page":"7464","volume-title":"Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines","author":"Falco","year":"2002","journal-title":"Oncogene"},{"key":"key-10.4103\/0973-1482.251622-7","first-page":"755","volume-title":"Identification of multiple cyclin subunits of human P-TEFb","author":"Peng","year":"1998","journal-title":"Genes Dev"},{"key":"key-10.4103\/0973-1482.251622-8","first-page":"34527","volume-title":"Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription","author":"Fu","year":"1999","journal-title":"J Biol Chem"},{"key":"key-10.4103\/0973-1482.251622-9","first-page":"15","volume-title":"Cellular control of gene expression by T-type cyclin\/CDK9 complexes","author":"Garriga","year":"2004","journal-title":"Gene"},{"key":"key-10.4103\/0973-1482.251622-10","first-page":"2622","volume-title":"Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro","author":"Zhu","year":"1997","journal-title":"Genes Dev"},{"key":"key-10.4103\/0973-1482.251622-11","first-page":"451","volume-title":"A novel CDK9-associated C-type cyclin interacts directly with HIV-1 tat and mediates its high-affinity, loop-specific binding to TAR RNA","author":"Wei","year":"1998","journal-title":"Cell"},{"key":"key-10.4103\/0973-1482.251622-12","first-page":"571","volume-title":"Activation of human cyclin-dependent kinases in vitro","author":"Desai","year":"1992","journal-title":"Mol Biol Cell"},{"key":"key-10.4103\/0973-1482.251622-13","first-page":"342","volume-title":"CDK9: From basal transcription to cancer and AIDS","author":"De","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"key-10.4103\/0973-1482.251622-14","first-page":"1111","volume-title":"Discovery and characterization of 2-anilino-4- (thiazol-5-yl) pyrimidine transcriptional CDK inhibitors as anticancer agents","author":"Wang","year":"2010","journal-title":"Chem Biol"},{"key":"key-10.4103\/0973-1482.251622-15","first-page":"6500","volume-title":"4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects","author":"Krystof","year":"2006","journal-title":"J Med Chem"},{"key":"key-10.4103\/0973-1482.251622-16","first-page":"931","volume-title":"Halogen bonds form the basis for selective P-TEFb inhibition by DRB","author":"Baumli","year":"2010","journal-title":"Chem Biol"},{"key":"key-10.4103\/0973-1482.251622-17","first-page":"280","volume-title":"Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9","author":"Schmerwitz","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key-10.4103\/0973-1482.251622-18","first-page":"369","volume-title":"CDK inhibitors roscovitine and CR8 trigger mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells","author":"Bettayeb","year":"2010","journal-title":"Genes Cancer"},{"key":"key-10.4103\/0973-1482.251622-19","first-page":"1086","volume-title":"Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9","author":"Berberich","year":"2011","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/0973-1482.251622-20","first-page":"4289","volume-title":"The selective P-TEFb inhibitor CAN508 targets angiogenesis","author":"Kry\u0161tof","year":"2011","journal-title":"Eur J Med Chem"},{"key":"key-10.4103\/0973-1482.251622-21","first-page":"2883","volume-title":"Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target","author":"Krystof","year":"2012","journal-title":"Curr Pharm Des"},{"key":"key-10.4103\/0973-1482.251622-22","first-page":"376","volume-title":"Preclinical and clinical development of cyclin-dependent kinase modulators","author":"Senderowicz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0973-1482.251622-23","first-page":"28","volume-title":"Targeting cancer with small molecule kinase inhibitors","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"key-10.4103\/0973-1482.251622-24","first-page":"708","volume-title":"Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors","author":"Rella","year":"2006","journal-title":"J Chem Inf Model"},{"key":"key-10.4103\/0973-1482.251622-25","first-page":"703","volume-title":"High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening","author":"Steindl","year":"2006","journal-title":"J Comput Aided Mol Des"},{"key":"key-10.4103\/0973-1482.251622-26","first-page":"773","volume-title":"Efficient overlay of small organic molecules using 3D pharmacophores","author":"Wolber","year":"2006","journal-title":"J Comput Aided Mol Des"},{"key":"key-10.4103\/0973-1482.251622-27","first-page":"575","volume-title":"Pharmacophore modeling and parallel screening for PPAR ligands","author":"Markt","year":"2007","journal-title":"J Comput Aided Mol Des"},{"key":"key-10.4103\/0973-1482.251622-28","first-page":"7","volume-title":"Ligand-based pharmacophore modeling and virtual screening of RAD9 inhibitors","author":"Prasad","year":"2013","journal-title":"J Chem"},{"key":"key-10.4103\/0973-1482.251622-29","first-page":"5995","volume-title":"Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17\u03b2-hydroxysteroid dehydrogenase 2 inhibitors","author":"Vuorinen","year":"2014","journal-title":"J Med Chem"},{"key":"key-10.4103\/0973-1482.251622-30","first-page":"22799","volume-title":"Pharmacophore models and pharmacophore-based virtual screening: Concepts and applications exemplified on hydroxysteroid dehydrogenases","author":"Kaserer","year":"2015","journal-title":"Molecules"},{"key":"key-10.4103\/0973-1482.251622-31","first-page":"8071","volume-title":"A combinatorial approach for the discovery of cytochrome P450 2D6 inhibitors from nature","author":"Hochleitner","year":"2017","journal-title":"Sci Rep"},{"key":"key-10.4103\/0973-1482.251622-32","first-page":"1229","volume-title":"Identification of novel inhibitors against cyclin dependent kinase 9\/cyclin T1 complex as: Anti cancer agent","author":"Hussain","year":"2017","journal-title":"Saudi J Biol Sci"},{"key":"key-10.4103\/0973-1482.251622-33","first-page":"3915","volume-title":"Virtual screening, synthesis and biological evaluation of DNA intercalating antiviral agents","author":"Klimenko","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"key-10.4103\/0973-1482.251622-34","first-page":"1364","volume-title":"Structure based in silico identification of potentially non-steroidal brassinosteroids mimics","author":"Lei","year":"2017","journal-title":"Mol Biosyst"},{"key":"key-10.4103\/0973-1482.251622-35","first-page":"1399","volume-title":"A molecular dynamics-shared pharmacophore approach to boost early-enrichment virtual screening: A case study on peroxisome proliferator-activated receptor \u03b1","author":"Perricone","year":"2017","journal-title":"ChemMedChem"},{"key":"key-10.4103\/0973-1482.251622-36","first-page":"365","volume-title":"Common hits approach: Combining pharmacophore modeling and molecular dynamics simulations","author":"Wieder","year":"2017","journal-title":"J Chem Inf Model"},{"key":"key-10.4103\/0973-1482.251622-37","first-page":"494","volume-title":"Virtual screening strategies in drug discovery","author":"McInnes","year":"2007","journal-title":"Curr Opin Chem Biol"},{"key":"key-10.4103\/0973-1482.251622-38","first-page":"303","volume-title":"Docking-based virtual screening: Recent developments","author":"Tuccinardi","year":"2009","journal-title":"Comb Chem High Throughput Screen"},{"key":"key-10.4103\/0973-1482.251622-39","first-page":"660","volume-title":"Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity","author":"Hole","year":"2013","journal-title":"J Med Chem"},{"key":"key-10.4103\/0973-1482.251622-40","first-page":"1752","volume-title":"Integrated modeling program, applied chemical theory (IMPACT)","author":"Banks","year":"2005","journal-title":"J Comput Chem"},{"key":"key-10.4103\/0973-1482.251622-41","first-page":"6177","volume-title":"Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","author":"Friesner","year":"2006","journal-title":"J Med Chem"},{"key":"key-10.4103\/0973-1482.251622-42","first-page":"3","volume-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"key-10.4103\/0973-1482.251622-43","first-page":"327","volume-title":"In silico approaches for predicting ADME properties of drugs","author":"Yamashita","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"key-10.4103\/0973-1482.251622-44","first-page":"4805","volume-title":"Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring","author":"Lyne","year":"2006","journal-title":"J Med Chem"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:40:58Z","timestamp":1786714858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_47_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"alternative-id":["251622"],"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_47_18","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}